Holen Sie sich die Stockscreener-App
0.5808
2.91%
-0.0172
Schlusskurs vom Vortag:
$0.598
Offen:
$0.6046
24-Stunden-Volumen:
770.18K
Relative Volume:
0.15
Marktkapitalisierung:
$175.19M
Einnahmen:
$52.29M
Nettoeinkommen (Verlust:
$-134.84M
KGV:
-0.7744
EPS:
-0.75
Netto-Cashflow:
$-117.11M
1W Leistung:
-7.71%
1M Leistung:
-14.98%
6M Leistung:
-20.28%
1J Leistung:
-69.12%
1-Tages-Spanne:
$0.58
$0.6055
1-Wochen-Bereich:
$0.562
$0.6283
52-Wochen-Spanne:
$0.4111
$3.179
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Firmenname
Sangamo Therapeutics Inc
Sektor
Branche
Telefon
(510) 970-6000
Adresse
501 CANAL BLVD., RICHMOND, CA
Vergleichen Sie SGMO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.5807 | 180.42M | 52.29M | -134.84M | -117.11M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.50 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.50 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
441.12 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
828.79 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.35 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-13 | Hochstufung | Truist | Hold → Buy |
| 2024-12-10 | Bestätigt | H.C. Wainwright | Buy |
| 2023-11-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-04-28 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-02-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-06-13 | Fortgesetzt | Wedbush | Neutral |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-01-07 | Fortgesetzt | Guggenheim | Neutral |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-12-16 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-09-08 | Eingeleitet | BofA Securities | Buy |
| 2020-07-07 | Eingeleitet | SunTrust | Buy |
| 2019-08-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2018-10-10 | Eingeleitet | Guggenheim | Buy |
| 2018-06-20 | Eingeleitet | BofA/Merrill | Buy |
| 2017-11-15 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2016-11-01 | Herabstufung | Wedbush | Outperform → Neutral |
| 2016-10-19 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-10-23 | Fortgesetzt | Jefferies | Buy |
| 2013-05-03 | Eingeleitet | BioLogic Equity Research | Sell |
| 2011-02-23 | Bestätigt | JMP Securities | Mkt Outperform |
| 2010-07-29 | Bestätigt | Wedbush | Outperform |
| 2009-10-19 | Eingeleitet | Brean Murray | Sell |
| 2009-10-07 | Bestätigt | Leerink Swann | Outperform |
| 2009-08-25 | Bestätigt | JMP Securities | Mkt Outperform |
Alle ansehen
Sangamo Therapeutics Inc Aktie (SGMO) Neueste Nachrichten
Tick level data insight on Sangamo Therapeutics Inc. volatility2025 Major Catalysts & Fast Gain Stock Tips - newser.com
How buybacks impact Sangamo Therapeutics Inc. stock valueEarnings Miss & Daily Technical Stock Forecast Reports - newser.com
Is Sangamo Therapeutics Inc. stock a safe haven assetTreasury Yields & Weekly Chart Analysis and Trade Guides - newser.com
Will Sangamo Therapeutics Inc. stock outperform Nasdaq indexTrade Risk Report & Free Long-Term Investment Growth Plans - newser.com
How Sangamo Therapeutics Inc. stock reacts to bond yieldsEarnings Risk Report & Risk Managed Investment Entry Signals - newser.com
Real time pattern detection on Sangamo Therapeutics Inc. stock2025 Winners & Losers & Growth Focused Stock Pick Reports - newser.com
Using AI based signals to follow Sangamo Therapeutics Inc.Market Trend Review & Safe Capital Preservation Plans - newser.com
Detecting price anomalies in Sangamo Therapeutics Inc. with AIJuly 2025 Decliners & Free Daily Entry Point Trade Alerts - newser.com
What machine learning models say about Sangamo Therapeutics Inc.Profit Target & AI Based Trade Execution Alerts - newser.com
Sangamo Therapeutics Inc. stock chart pattern explainedMarket Activity Summary & Daily Entry Point Trade Alerts - newser.com
How Sangamo Therapeutics Inc. (GBY) stock reacts to monetary easingJuly 2025 Outlook & Stepwise Entry/Exit Trade Alerts - newser.com
Is Sangamo Therapeutics Inc. stock in correction or buying zoneMarket Growth Report & Smart Allocation Stock Tips - newser.com
Published on: 2025-10-31 05:14:43 - newser.com
How hedge fund analytics apply to Sangamo Therapeutics Inc. stock2025 Earnings Surprises & Stepwise Trade Signal Guides - newser.com
Why retail investors favor Sangamo Therapeutics Inc. stockJuly 2025 Chart Watch & Reliable Momentum Entry Alerts - newser.com
What analyst consensus says on Sangamo Therapeutics Inc. stockTrade Risk Report & Fast Exit/Entry Strategy Plans - newser.com
What analysts say about Sangamo Therapeutics Inc stockEarnings Per Share Trends & Big Returns, Small Investment – Learn How - earlytimes.in
Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call - The Manila Times
We're Hopeful That Sangamo Therapeutics (NASDAQ:SGMO) Will Use Its Cash Wisely - Yahoo Finance
Published on: 2025-10-29 21:25:18 - newser.com
Sangamo Biosciences Granted Nasdaq Compliance Extension - TipRanks
Published on: 2025-10-27 19:21:18 - newser.com
Finanzdaten der Sangamo Therapeutics Inc-Aktie (SGMO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.21%
0.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):